Precigen (I5X) AI Stock Analysis

1 Followers

Precigen

(Frankfurt:I5X)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

PAPZIMEOS GrowthRapid sequential product growth, alongside substantial launch-to-date revenue, indicates that PAPZIMEOS is gaining commercial traction rather than relying only on development partnerships. Continued patient enrollment, site activation and payer access could support durable revenue expansion over the next several quarters.

Negative Factors

Persistent Cash BurnDeeply negative trailing cash flow means improving reported earnings have not yet translated into sustained cash generation. Persistent burn can reduce financial flexibility and leave the company more dependent on collections, financing or successful commercial execution to fund operations and development.

Precigen (I5X) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.81B
Dividend Yield: ―
Average Volume (3M): 569
Price to Earnings (P/E): -159.5
Beta (1Y): 0.74
Revenue Growth: 1733.82%
EPS Growth: -135.53%
Country: Germany
Employees: 160
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Precigen Business Overview & Revenue Model

Company Description

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced r...

Precigen Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Mar 01, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by 37% sequential PAPZIMEOS revenue growth, profitability, positive operating cash flow ahead of guidance, broad payer coverage, rapid patient adoption and continued pipeline and platform expansion. The principal challenge discussed was the arrival of competition, while the company also carries $100 million of outstanding debt and associated interest expense.

Positive Updates

Strong PAPZIMEOS Revenue Growth

Third-quarter PAPZIMEOS net product revenue was $72.9 million, bringing launch-to-date revenue through the end of Q3 to approximately $151 million. Revenue increased from $53 million in Q2 to approximately $73 million in Q3, representing approximately $20 million or 37% sequential growth.

Negative Updates

Emerging Competitive Threat

A competitor therapy for RRP recently received conditional approval, and Inovio has indicated that it expects to launch in the new year. Management said competition had been anticipated and that new entrants will need to establish physician confidence, payer access, treatment-site capabilities and commercial infrastructure.

Company Guidance

Precigen did not provide guidance for the fourth quarter, but said it feels very good about Q4 and its growth prospects, expects to continue converting a significant proportion of patients in the hub to treatment, and expects both hub and non-hub patients to be significant contributors to future growth; it continues to expect gross margins related to U.S. PAPZIMEOS sales to stabilize between the high 80 percentages and low 90 percentages going forward, expects to collect $96.5 million in trade accounts receivable over the 4 months following quarter end, does not currently anticipate a need to raise additional capital, and said it expects to have data and reporting from the redosing trial in 2020.

Precigen Risk Analysis

Precigen disclosed 67 risk factors in its most recent earnings report. Precigen reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Item 3. Defaults on Senior SecuritiesQ2, 2026

2.Item 5. Other InformationQ2, 2026

3.Item 4. Mine Safety DisclosuresQ2, 2026

Precigen Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:I5X against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	58Neutral	$1.66B	-3.66	-57.79%	―	12.58%	28.42%
OBX	54Neutral	$817.26M	0.05	-210.64%	―	―	―
QURE	52Neutral	$1.66B	-6.50	-96.34%	―	30.24%	-3.25%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SANA	49Neutral	$730.44M	-3.37	-134.49%	―	―	28.46%
SLDB	39Underperform	$673.37M	-4.56	-72.28%	―	―	31.81%

* Healthcare Sector Average

Performance Comparison

DE:I5X and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:I5X	Precigen, Inc.	4.33	0.99	29.72%
QURE	uniQure N.V.	23.03	-4.48	-16.28%
NTLA	Intellia Therapeutics Inc	12.31	-0.01	-0.08%
SLDB	Solid Biosciences	6.52	2.30	54.50%
OBX	Obsidian Therapeutics, Inc.	10.99	6.39	138.91%
SANA	Sana Biotechnology, Inc.	2.56	-1.49	-36.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Precigen AI Stock Analysis